BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) Advances Breast Cancer Therapy Trials to Patient Dosing Stage
Breast cancer is the leading cancer diagnosed in women and the second-most common cancer overall BriaCell Therapeutics has begun patient dosing in clinical trials that combine its trademarked Bria-IMT technology with celebrated cancer-fighting antibodies The clinical trials are working on a therapy that will help the body’s own immune system fight cancerous cells The battle against breast cancer is taking a technological turn amid an increasing drive to develop therapies that use the body’s own immune system to destroy life-threatening cancer cells. BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT) is on the front line of the battle and is currently…